Coronary Revascularization in Patients With Cancer.

IF 0.8 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Treatment Options in Cardiovascular Medicine Pub Date : 2023-01-01 Epub Date: 2023-04-21 DOI:10.1007/s11936-023-00982-9

Bala Pushparaji, Teodora Donisan, Dinu Valentin Balanescu, Jong Kun Park, Dominique J Monlezun, Abdelrahman Ali, Ibrahim Halil Inanc, Jaime Caballero, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu

{"title":"Coronary Revascularization in Patients With Cancer.","authors":"Bala Pushparaji, Teodora Donisan, Dinu Valentin Balanescu, Jong Kun Park, Dominique J Monlezun, Abdelrahman Ali, Ibrahim Halil Inanc, Jaime Caballero, Mehmet Cilingiroglu, Konstantinos Marmagkiolis, Cezar Iliescu","doi":"10.1007/s11936-023-00982-9","DOIUrl":null,"url":null,"abstract":"Purpose of review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage.Recent findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing.Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology - Cardio-oncology guidelines in 2022.","PeriodicalId":35912,"journal":{"name":"Current Treatment Options in Cardiovascular Medicine","volume":"25 6","pages":"143-158"},"PeriodicalIF":0.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119009/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Cardiovascular Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11936-023-00982-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/21 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The treatment of coronary artery disease (CAD) in cancer patients is an evolving landscape. Recent data emphasizes the importance of aggressive management of cardiovascular risk factors and diseases in improving cardiovascular health in this unique group of patients regardless of cancer type or stage.

Recent findings: Novel cancer therapeutics such as immune therapies and proteasome inhibitors have been associated with CAD. Recent stent technologies may safely allow for shorter duration (< 6 months) of dual antiplatelet therapy post-percutaneous coronary interventions. Intracoronary imaging may be useful in the decision making process in terms of stent positioning and healing.

Summary: Large registry studies have partially filled a gap left by the lack of randomized controlled trials in the treatment of CAD in cancer patients. Cardio-oncology is gaining traction as a major sub-specialty in the cardiology field given the release of the first European Society of Cardiology - Cardio-oncology guidelines in 2022.

查看原文本刊更多论文

癌症患者的冠状动脉血运重建。

综述目的：癌症患者冠状动脉疾病（CAD）的治疗是一个不断发展的过程。最近的数据强调了积极治疗心血管危险因素和疾病对改善这一特殊患者群体心血管健康的重要性，无论癌症类型或阶段如何：免疫疗法和蛋白酶体抑制剂等新型癌症疗法与 CAD 有关。最新的支架技术可以安全地缩短治疗时间（摘要：大型登记研究部分填补了癌症患者的 CAD 治疗缺乏随机对照试验的空白。鉴于 2022 年欧洲心脏病学会发布了第一份《心脏病学-肿瘤学指南》，肿瘤心脏病学作为心脏病学领域的一个重要亚专科正受到越来越多的关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published treatment-related advances in cardiovascular medicine. By providing clear, insightful, balanced contributions by international experts, the journal intends to elucidate novel approaches to treatment in those affected by the spectrum of cardiovascular-related diseases and conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as coronary artery disease, cerebrovascular disease and stroke, heart failure, pediatric and congenital heart disease, and valvular, myocardial, pericardial, and cardiopulmonary diseases. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known figures in the field, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.